CG Oncology Q1 net loss widens to $60.2M; BLA submission on track for Q4 2026

CG Oncology, Inc.

2026-Q1 EPS reported -$0.71 revenue$1,083,000

Net loss of $60.2M ($0.71 per share) vs $34.5M ($0.45) in Q1 2025.
Cash, cash equivalents & marketable securities $1.1B as of March 31, 2026; includes $391.4M from ATM sales.
BLA for cretostimogene in HR BCG-unresponsive NMIBC expected to complete in Q4 2026 after FDA alignment.
Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC anticipated 1H 2026.
Appointed Jim DeTore as CFO in April 2026; he brings 30+ years life sciences experience.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CG Oncology, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $60.2 million, or $(0.71) per share, EPS $(0.71) per share.

Period: the first quarter ended March 31, 2026
Net income: Net loss was $60.2 million, or $(0.71) per share
EPS: $(0.71) per share
Result: reported results

Exact text from the filing

an increase in personnel-related expenses, including compensation costs from increased headcount, and an increase in professional and consulting fees. • Net Loss : Net loss was $60.2 million, or $(0.71) per share, for the first quarter of 2026, as compared to a net loss of $34.5 million, or $(0.45) per share, for the prior year period.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

CG Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-213440

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.